MAPK3 and neoplasm: ERK1/2 kinaseslocalize at the crossroads of various signaling pathways, since they are a keynode in activating the emergency survival program of tumor cells after theapplication of receptor tyrosine kinase inhibitors and standard chemotherapy[9].